Avidea Technologies

Avidea Technologies is a privately held biotechnology company headquartered in Baltimore, Maryland, United States. The company is active in the life sciences sector, focusing on research and development in immunotherapy and vaccine technologies. Its work falls within the broader fields of immuno-oncology and infectious disease, utilizing novel delivery platforms and immunomodulatory approaches to improve therapeutic and preventive outcomes. As a Baltimore-based enterprise, Avidea Technologies is part of the growing biotechnology and research ecosystem of the U.S. Mid-Atlantic region, which is home to major academic and medical institutions. The company's location places it near a dense network of research hospitals, universities, and life sciences talent that supports early-stage and translational biotechnology ventures. Avidea Technologies' official website is avideatechnologies.com, which serves as its primary channel for public company information. The company is privately held, with no public listing or stock ticker. Available evidence does not provide detailed information on its founding year, founders, ownership structure, or specific product pipeline, so this profile does not assert such details. Given the limited public evidence, this entry should be regarded as a basic corporate profile. Further verified information on the company's financing, partnerships, clinical programs, and leadership would be needed to expand the profile.

Avidea Technologies is a biotechnology company based in Baltimore, Maryland, United States. The available evidence identifies it as a company located in Baltimore, but does not provide a founding date, founding team, or a detailed corporate history. As a result, a chronological account of its origins and development cannot be constructed from the supplied sources. What can be stated is that the company is part of Baltimore's life-science and biotechnology community. Baltimore and the surrounding Mid-Atlantic region host a substantial concentration of academic research institutions, teaching hospitals, and federal research facilities, which collectively form an environment conducive to the formation and growth of early-stage biotechnology ventures. Companies in this ecosystem typically engage in research and development activities that may include preclinical studies, platform technology development, and collaborations with academic or clinical partners. Avidea Technologies maintains a public web presence at avideatechnologies.com. The company is privately held, and there is no indication in the evidence of a public listing, ticker symbol, or acquisition by a larger corporate parent. No verified information about its financing rounds, investors, leadership appointments, product pipeline milestones, or partnerships is available in the supplied evidence. Because the evidence is limited to the company's identity and location, this history section remains intentionally brief. Any expansion of the company's historical narrative would require additional verified sources, such as corporate filings, press releases, or reputable news coverage.

Early-stage biotechnology company focused on immunotherapies and vaccine technologies.

• 2021-12-14

  Vaccitech acquires Avidea Technologies[3]Vaccitech 收购 Avidea Technologiesbaltimoresun.com

  Reported: 2021-12-14

  Vaccitech acquired Avidea Technologies for $40 million, paying $12.5 million in cash and $27.5 million in Vaccitech American depository shares.

1. 1Avidea Technologies (United States) - Wikidatawikidata.org
2. 2Avidea Technologies official websiteavideatechnologies.com
3. 3Vaccitech 收购 Avidea Technologiesbaltimoresun.com